☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
diabetic retinopathy
Regenxbio Presented Interim Results of RGX-314 in P-II AAVIATE and ALTITUDE Trials for Wet AMD and Diabetic Retinopathy at AAO 202...
November 15, 2021
Regenxbio Presents Results of RGX-314 in P-II ALTITUDE Trial for the Treatment of Diabetic Retinopathy at ASRS Annual Meeting
October 11, 2021
AbCellera Signs a Multi-Target Collaboration with Angios to Develop Bispecific Antibodies for the Treatment of Diabetic Retinopath...
May 7, 2021
Boehringer Ingelheim and Pharmaxis Halt the Development of BI 1467335 for Diabetic Retinopathy
September 8, 2020
Regeneron Reports Results of Eylea (aflibercept) in P-III PANORAMA Study for Patients with Diabetic Retinopathy
February 10, 2020
Regeneron's Eylea (aflibercept) Injection Receives FDA's Approval for Diabetic Retinopathy
May 14, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.